A Clinician's Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (RADAR III)

E. David Crawford*, Phillip J. Koo, Neal Shore, Susan F. Slovin, Raoul S. Concepcion, Stephen J. Freedland, Leonard G. Gomella, Lawrence Karsh, Thomas E. Keane, Paul Maroni, David Penson, Daniel P. Petrylak, Ashley Ross, Vlad Mouraviev, Robert E. Reiter, Chaitanya Divgi, Evan Y. Yu

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

43 Scopus citations


Purpose:The advanced prostate cancer therapeutic landscape has changed dramatically in the last several years, resulting in improved overall survival of patients with castration naïve and castration resistant disease. The evolution and development of novel next generation imaging techniques will affect diagnostic and therapeutic decision making. Clinicians must navigate when and which next generation imaging techniques to use and how to adjust treatment strategies based on the results, often in the absence of correlative therapeutic data. Therefore, guidance is needed based on best available information and current clinical experience.Materials and Methods:The RADAR (Radiographic Assessments for Detection of Advanced Recurrence) III Group convened to offer guidance on the use of next generation imaging to stage prostate cancer based on available data and clinical experience. The group also discussed the potential impact of next generation imaging on treatment options based on earlier detection of disease.Results:The group unanimously agreed that progression to metastatic disease is a seminal event for patient treatment. Next generation imaging techniques are able to detect previously undetectable metastases, which could redefine the phases of prostate cancer progression. Thus, earlier systemic or locally directed treatment may positively alter patient outcomes.Conclusions:The RADAR III Group recommends next generation imaging techniques in select patients in whom disease progression is suspected based on laboratory (biomarker) values, comorbidities and symptoms. Currently 18F-fluciclovine and 68Ga prostate specific membrane antigen positron emission tomography/computerized tomography are the next generation imaging agents with a favorable combination of availability, specificity and sensitivity. There is ongoing research of additional next generation imaging technologies, which may offer improved diagnostic accuracy and therapeutic options. As next generation imaging techniques evolve and presumably result in improved global accessibility, clinician ability to detect micrometastases may be enhanced for decision making and patient outcomes.

Original languageEnglish (US)
Pages (from-to)682-692
Number of pages11
JournalJournal of Urology
Issue number4
StatePublished - Apr 1 2019
Externally publishedYes


  • clinical decision-making
  • diagnostic imaging
  • neoplasm metastasis
  • practice guideline
  • prostatic neoplasms

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'A Clinician's Guide to Next Generation Imaging in Patients with Advanced Prostate Cancer (RADAR III)'. Together they form a unique fingerprint.

Cite this